Vivos Therapeutics Inc. shares jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea. The U.S ...

New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and ChildrenLITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE ...

Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos’ devices, designed to treat obstructive sleep apnea (OSA) in both adults and children.

New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos ...

Designed to reduce nighttime snoring and treat moderate to severe obstructive sleep apnea in children aged 6 to 17, this Vivos device is intended for those diagnosed with snoring and/or OSA who ...

such as lowering Apnea Hypopnea Index scores. Vivos also employs a marketing and distribution model where it collaborates with sleep-treatment providers to offer patients OSA treatment options and ...

Vivos Therapeutics, Inc. is a medical technology ... Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh ...

including obstructive sleep apnea (OSA) in adults and children, today announced the American Medical Association (AMA) has issued new CPT® medical codes applicable to all Vivos CARE oral medical ...

New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and ChildrenLITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos ...

Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...